U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C14H27O2.C6H14N2.Pt.H2O
Molecular Weight 782.014
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIRIPLATIN MONOHYDRATE

SMILES

O.[Pt++].N[C@@H]1CCCC[C@H]1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O

InChI

InChIKey=LWDBMUAJGMXQAY-GSEQGPDBSA-L
InChI=1S/2C14H28O2.C6H14N2.H2O.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;1H2;/q;;;;+2/p-2/t;;5-,6-;;/m..1../s1

HIDE SMILES / InChI

Molecular Formula C6H14N2
Molecular Weight 114.1888
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C14H28O2
Molecular Weight 228.3709
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Miriplatin hydrate was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Oct 16, 2009. It was developed and marketed as Miripla® by Dainippon Sumitomo Pharma on Jan 20, 2010 in Japan. Miriplatin hydrate is a lipophilic platinum complex that has high affinity to lipiodol. It is indicated for the treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma. Miripla® is available as lyophilized powder for arterial injection, containing 70 mg of free Miriplatin. The recommended dose is 70 mg once daily.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MIRIPLA

Approved Use

Lipiodolization in hepatocellular carcinoma

Launch Date

2009
PubMed

PubMed

TitleDatePubMed
In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
2000 Jan
Patents

Sample Use Guides

70 mg of miriplatin is suspended in 3.5 mL of suspension vehicle for this drug, and administered once a day through catheter inserted into hepatic artery. Administration of miriplatin-suspension ends when tumor vessel is filled with the drug, provided that the upper limit should be 6 mL per administration (equivalent to 120 mg of miriplatin). An observation period of 4 weeks or longer is required in the case of repeated administration.
Route of Administration: Intra-arterial
Miriplatin (SM-11355) suspended in Lipiodol (SM-11355/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. IC50 value following 7-day exposure was 22.3 ug/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:09:20 GMT 2023
Edited
by admin
on Sat Dec 16 05:09:20 GMT 2023
Record UNII
75H6U03J2H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIRIPLATIN MONOHYDRATE
Common Name English
PLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N,.KAPPA.N')BIS(TETRADECANOATO-.KAPPA.O)-, MONOHYDRATE, (SP-4-2)-
Common Name English
MIRIPLATIN HYDRATE [JAN]
Common Name English
MIRIPLATIN HYDRATE [MI]
Common Name English
MIRIPLATIN HYDRATE
JAN  
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID50179715
Created by admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
PRIMARY
SMS_ID
100000127453
Created by admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
PRIMARY
CAS
250159-48-9
Created by admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
PRIMARY
EVMPD
SUB33476
Created by admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
PRIMARY
FDA UNII
75H6U03J2H
Created by admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
PRIMARY
PUBCHEM
23725065
Created by admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
PRIMARY
MERCK INDEX
m11894
Created by admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY